Zimmer Biomet Holdings Management
Management criteria checks 2/4
Zimmer Biomet Holdings' CEO is Ivan Tornos, appointed in Aug 2023, has a tenure of 2.08 years. total yearly compensation is $14.99M, comprised of 8.3% salary and 91.7% bonuses, including company stock and options. directly owns 0.026% of the company’s shares, worth CHF4.37M. The average tenure of the management team and the board of directors is 4.4 years and 7.1 years respectively.
Key information
Ivan Tornos
Chief executive officer
US$15.0m
Total compensation
| CEO salary percentage | 8.25% |
| CEO tenure | 2.1yrs |
| CEO ownership | 0.03% |
| Management average tenure | 4.4yrs |
| Board average tenure | 7.1yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | US$824m |
| Mar 31 2025 | n/a | n/a | US$913m |
| Dec 31 2024 | US$15m | US$1m | US$904m |
| Sep 30 2024 | n/a | n/a | US$1b |
| Jun 30 2024 | n/a | n/a | US$997m |
| Mar 31 2024 | n/a | n/a | US$964m |
| Dec 31 2023 | US$10m | US$969k | US$1b |
| Sep 30 2023 | n/a | n/a | US$474m |
| Jun 30 2023 | n/a | n/a | US$506m |
| Mar 31 2023 | n/a | n/a | US$450m |
| Dec 31 2022 | US$6m | US$823k | US$290m |
| Sep 30 2022 | n/a | n/a | US$366m |
| Jun 30 2022 | n/a | n/a | US$334m |
| Mar 31 2022 | n/a | n/a | US$325m |
| Dec 31 2021 | US$5m | US$731k | US$445m |
| Sep 30 2021 | n/a | n/a | US$834m |
| Jun 30 2021 | n/a | n/a | US$914m |
| Mar 31 2021 | n/a | n/a | US$563m |
| Dec 31 2020 | US$4m | US$730k | -US$11m |
| Sep 30 2020 | n/a | n/a | -US$152m |
| Jun 30 2020 | n/a | n/a | US$37m |
| Mar 31 2020 | n/a | n/a | US$377m |
| Dec 31 2019 | US$4m | US$700k | US$1b |
| Sep 30 2019 | n/a | n/a | -US$90m |
| Jun 30 2019 | n/a | n/a | -US$359m |
| Mar 31 2019 | n/a | n/a | -US$308m |
| Dec 31 2018 | US$4m | US$113k | -US$379m |
Compensation vs Market: Ivan's total compensation ($USD14.99M) is above average for companies of similar size in the UK market ($USD6.72M).
Compensation vs Earnings: Ivan's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Ivan Tornos (50 yo)
Mr. Ivan Tornos was President, CEO & Director of Zimmer Biomet Holdings, Inc. from August 2023. Mr. Ivan Tornos is President, CEO & Chairman of the Board of Zimmer Biomet Holdings, Inc. from May 29, 2025....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.1yrs | US$14.99m | 0.026% CHF 4.4m | |
| CFO and Executive VP of Finance | 6.2yrs | US$5.88m | 0.025% CHF 4.1m | |
| Group President of Asia Pacific | 10.3yrs | US$3.15m | 0.0099% CHF 1.7m | |
| Group President of Europe | 4.3yrs | US$3.48m | 0.011% CHF 1.8m | |
| VP, Controller & Chief Accounting Officer | 3.3yrs | no data | 0.0019% CHF 312.7k | |
| Senior VP & Chief Information and Technology Officer | 1.3yrs | no data | no data | |
| Senior Vice President of Investor Relations | 1yr | no data | no data | |
| Senior VP | 18.3yrs | US$2.87m | 0.030% CHF 5.1m | |
| Senior VP | 10.3yrs | no data | no data | |
| Senior VP & Chief Communications Officer | less than a year | no data | no data | |
| Senior VP & Chief Human Resources Officer | 4.5yrs | no data | 0.0042% CHF 703.9k | |
| Senior Vice President of Global Quality & Regulatory Affairs | 9.4yrs | no data | no data |
Experienced Management: 0QQD's management team is considered experienced (4.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.1yrs | US$14.99m | 0.026% CHF 4.4m | |
| Independent Director | 16.7yrs | US$348.35k | 0.0027% CHF 444.7k | |
| Independent Director | 17.5yrs | US$366.68k | 0.0020% CHF 337.7k | |
| Independent Director | 18.6yrs | US$346.12k | 0.0017% CHF 287.6k | |
| Independent Director | 1.7yrs | US$370.41k | 0% CHF 0 | |
| Independent Director | 7.1yrs | US$322.57k | 0.00083% CHF 138.8k | |
| Lead Independent Director | 10.8yrs | US$348.37k | 0.0010% CHF 168.9k | |
| Independent Director | 1.3yrs | US$123.81k | 0% CHF 0 | |
| Independent Director | 4.6yrs | US$395.67k | 0.00050% CHF 83.6k | |
| Independent Director | 7.1yrs | US$375.18k | 0.0021% CHF 342.8k |
Experienced Board: 0QQD's board of directors are considered experienced (7.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/07 01:21 |
| End of Day Share Price | 2025/06/11 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zimmer Biomet Holdings, Inc. is covered by 62 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Stephan Gasteyger | Atlantic Equities LLP |
| Jeffrey Johnson | Baird |